Scientific deep-dive
How Long Do Zepbound, Wegovy and Other GLP-1s Stay in Your System?
Half-lives and washout times for tirzepatide (Zepbound, Mounjaro), semaglutide (Wegovy, Ozempic), liraglutide, dulaglutide, orforglipron and investigational retatrutide, from FDA labels and trial data, with what the labels say about stopping before pregnancy or surgery.
Tirzepatide, the drug in Zepbound and Mounjaro, has a half-life of about 5 to 6 days, so most of it is gone roughly a month after the last injection.[1][2] Semaglutide (Wegovy, Ozempic) lasts longer: it has a week-long half-life, and Wegovy’s label says it is still in the circulation 5 to 7 weeks after a last dose.[3] Daily liraglutide (Saxenda) is cleared within a few days.[5] The figures below come from each FDA label, with the trial estimate for retatrutide, which is not yet approved.
Half-life and the five half-lives rule
A drug’s half-life is how long the blood level takes to drop to half of where it was. Half remains after one; a quarter after two; roughly 3% after five. That is why pharmacists use five half-lives as a working estimate of when a drug has mostly washed out. It is arithmetic, and it fits what the semaglutide labels say directly: a half-life of about a week, and, per Ozempic’s label, roughly five weeks for the last dose to leave.[4]
The long half-lives are deliberate. Tirzepatide carries a fatty acid chain that binds it to albumin in the blood, which is how the label explains its once-weekly dosing.[1] The same albumin binding protects semaglutide from being filtered and broken down.[4]
How long each GLP-1 lasts
| Drug (brand) | Dosing | Half-life | Five half-lives, roughly | What the label adds |
|---|---|---|---|---|
| Tirzepatide (Zepbound) | Weekly injection | About 5 to 6 days | 25 to 30 days | Steady state is reached after 4 weeks of weekly doses |
| Tirzepatide (Mounjaro) | Weekly injection | About 5 days | About 25 days | Same molecule as Zepbound |
| Semaglutide (Wegovy injection or tablet) | Weekly injection or daily tablet | About 1 week | About 5 weeks | Label: still circulating 5 to 7 weeks after a last 2.4 mg or 7.2 mg shot or 25 mg tablet |
| Semaglutide (Ozempic) | Weekly injection | About 1 week | About 5 weeks | Label: still circulating about 5 weeks after a final dose |
| Semaglutide (Rybelsus, Ozempic tablets) | Daily tablet | About 1 week | About 5 weeks | Present for about five weeks after the last tablet |
| Liraglutide (Saxenda) | Daily injection | About 13 hours | About 3 days | Short half-life is why it is dosed every day |
| Dulaglutide (Trulicity) | Weekly injection | About 5 days | About 25 days | Steady state between 2 and 4 weeks |
| Orforglipron (Foundayo) | Daily tablet | 29 to 49 hours | About 6 to 10 days | Steady state after about 1 week |
| Retatrutide (investigational) | Weekly injection in trials | About 6 days | About 30 days | Phase 1b trial estimate; not an FDA label |
Sources for the rows: Zepbound,[1] Mounjaro,[2] Wegovy,[3] Ozempic,[4] Saxenda,[5] Trulicity,[6] Foundayo,[7] Rybelsus and Ozempic tablets[8] and retatrutide.[9] The fourth column is the half-life multiplied by five, rounded.
How long Zepbound and Mounjaro stay in your system
About a month. For tirzepatide in people treated for weight, Zepbound’s label puts the half-life at 5 to 6 days; Mounjaro’s label, written for diabetes, says about 5.[1][2] Five half-lives is 25 to 30 days. The label does not name a washout date for tirzepatide the way the semaglutide labels do, so the month is an estimate from the half-life rather than a figure Lilly prints. The washout calculator runs the same arithmetic from the date of your last dose.
Going the other way, levels build for about four weeks after you start or change a dose before they level off.[1] Compounded tirzepatide, where it actually contains tirzepatide at the stated strength, is the same molecule and clears on the same timetable.
How long semaglutide stays in your system
Five to seven weeks. Semaglutide is the one drug here whose label states the washout outright, and Wegovy’s does it in a single sentence:[3]
“With an elimination half-life of approximately 1 week, semaglutide will be present in the circulation for about 5 to 7 weeks after the last injectable dose of 2.4 mg or 7.2 mg or oral dose of 25 mg.”— Wegovy prescribing information, section 12.3
The tablet and the injection end up in the same place. The Wegovy pill is absorbed poorly, but what does get in has the same week-long half-life, and the Rybelsus label gives the same five weeks after a last tablet.[8]
Saxenda and Foundayo clear within days
Liraglutide’s half-life is about 13 hours, which is why Saxenda is injected every day.[5] Five half-lives is under three days. Orforglipron, the active ingredient in Foundayo, sits in between: 29 to 49 hours, so most of it is gone within a week or so of the last tablet.[7] For anyone who wants a drug that leaves quickly if a side effect appears, these two are the shortest-acting options, and our Foundayo explainer covers how orforglipron differs from the peptides.
Retatrutide
Retatrutide is still investigational, so there is no FDA label to quote. In its phase 1b trial in people with type 2 diabetes, the pharmacokinetics were dose-proportional and the half-life was approximately 6 days.[9] That puts it close to tirzepatide, with most of a dose cleared in about a month. No retatrutide product has FDA approval yet, which also means nobody can tell you how much retatrutide a given vial holds; retatrutide’s price and release date covers where the approval stands.
Stopping before a pregnancy
Here the half-life turns into an instruction. All three semaglutide labels ask women planning a pregnancy to come off the drug two months or more in advance, and each gives semaglutide’s slow clearance as the reason.[3][4][8] Two months is longer than the five to seven weeks the drug takes to clear, which leaves a margin.
The Zepbound, Saxenda and Foundayo labels name no interval before conception. Each says to stop the drug when a pregnancy is recognized.[1][5][7] Zepbound’s adds a separate warning for anyone on the pill: tirzepatide can make birth-control pills less reliable, so for the first month on the drug, and the month after every step up in dose, the label wants either a contraceptive that is not taken by mouth or a barrier method such as condoms on top.[1] Foundayo’s gives 30 days for the same purpose.[7] What to do when a label is silent is the subject of GLP-1s and trying to conceive.
Before surgery or an endoscopy
These drugs slow the emptying of the stomach, and the Zepbound and Wegovy labels warn of rare reports of food being inhaled into the lungs under general anesthesia or deep sedation. Zepbound’s label says the available data are insufficient to say whether stopping the drug beforehand reduces that risk, and it asks patients to tell their providers before any planned procedure.[1][3] The half-life tells you how long the drug lingers; how long to hold it before a procedure is a decision for the team doing the procedure, and the current guidance is set out in GLP-1s before endoscopy and surgery.
When the effects wear off
The effects fade as the level in the blood falls, so they do not switch off on a particular day. Weight regain follows over months rather than weeks, and the trial evidence on that is in what happens when you stop a GLP-1. If you stop and then restart, the half-life matters again: the Wegovy label says that after two or more missed weekly doses the dose should be built up again from a lower step, to limit stomach side effects.[3]
Common questions
Frequently Asked Questions
References
- 1.Eli Lilly and Company ZEPBOUND (tirzepatide) injection: US Prescribing Information, sections 5.9, 8.1, 8.3 and 12.3 DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
- 2.Eli Lilly and Company MOUNJARO (tirzepatide) injection: US Prescribing Information, section 12.3 DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
- 3.Novo Nordisk Inc. WEGOVY (semaglutide) injection and tablets: US Prescribing Information, sections 2.4, 5.10, 8.3 and 12.3 DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- 4.Novo Nordisk Inc. OZEMPIC (semaglutide) injection: US Prescribing Information, sections 8.3 and 12.3 DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
- 5.Novo Nordisk Inc. SAXENDA (liraglutide) injection: US Prescribing Information, sections 8.1 and 12.3 DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
- 6.Eli Lilly and Company TRULICITY (dulaglutide) injection: US Prescribing Information, section 12.3 DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309
- 7.Eli Lilly and Company FOUNDAYO (orforglipron) tablets: US Prescribing Information, sections 8.1, 8.3 and 12.3 DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
- 8.Novo Nordisk Inc. RYBELSUS and OZEMPIC (oral semaglutide) tablets: US Prescribing Information, sections 8.3 and 12.3 DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
- 9.Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial Lancet. 2022. PMID: 36354040.
Compare the sellers
Related research
One Trial on Fertility
A systematic review searched five databases for everything on weight-lowering drugs and natural female fertility. It found seven trials, six of them on orlistat, and exactly one on a GLP-1.
6 min read
Does Ozempic Slow Your Metabolism? What the Measurements Show
Ozempic does not slow metabolism beyond what weight loss itself does. Calorimetry studies of semaglutide and tirzepatide found the drop in calorie burn matched the lost weight, and was no bigger than with dieting. What happens to muscle, plateaus and metabolism after stopping.
11 min read
Stopping Tirzepatide (Zepbound): Weight Regain, Side Effects and Cold Turkey
In SURMOUNT-4, people switched from tirzepatide to placebo regained 14% of body weight in a year, most of it in the first six months. What the Zepbound label says about stopping, the 5-day half-life, diabetes, and what helps keep weight off.
11 min read
Is Ozempic a Peptide? What Semaglutide and Tirzepatide Are Made Of
Yes. The molecules behind all four big brands, semaglutide and tirzepatide, are synthetic peptides; orforglipron (Foundayo) is not. What each is built from, why peptides are injected, why FDA calls them drugs rather than biologics, and what else is in the pen.
10 min read
How to Join a GLP-1 Clinical Trial: Finding a Real Obesity Drug Study
How to find a recruiting obesity-drug trial on ClinicalTrials.gov, who qualifies, your odds of placebo, what trials pay under FDA rules, your consent rights, why the drug usually stops when the trial ends, and how to spot fake trials.
12 min read
Which Drugs Are GLP-1s? Mounjaro, Trulicity, Phentermine and 25 More, Checked
Ozempic, Wegovy, Rybelsus, Trulicity and Foundayo are GLP-1 receptor agonists; Mounjaro and Zepbound add GIP. Phentermine, Contrave, metformin, Jardiance, Januvia and insulin are not. 28 drugs sorted by what each FDA label calls them.
10 min read